试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-05
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
编号:NCT02812693登记状态:入组前撤回企业 / 申办者:Joanne Jeter
药物 / 成分:Imatinib Mesylate、Laboratory Biomarker Analysis、Pembrolizumab
登记的停止原因(原文):poor accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-05
Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
编号:NCT03061136登记状态:入组前撤回企业 / 申办者:Palo Alto Veterans Institute for Research
药物 / 成分:Clonazepam、Placebo
登记的停止原因(原文):Delays in equipment procurement prevented the start of the study in time
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-05
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
编号:NCT03369964登记状态:入组前撤回企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Atezolizumab、Emactuzumab、Obinutuzumab
登记的停止原因(原文):Business decision: no safety or efficacy concerns.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-05
A Study of PTS for Patients With Solid Tumors
编号:NCT03448211登记状态:入组前撤回企业 / 申办者:PTS International Inc.
药物 / 成分:Para-toluenesulfonamide Injection (PTS)
登记的停止原因(原文):Development strategy reasons
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-04
Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
编号:NCT02048085登记状态:入组前撤回企业 / 申办者:Medical Center of South Arkansas
药物 / 成分:Ticagrelor、Clopidogrel
登记的停止原因(原文):unable to get study up and enrolling
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-02
Apremilast Therapy for Acute Gouty Arthritis
编号:NCT00997581登记状态:入组前撤回企业 / 申办者:Dartmouth-Hitchcock Medical Center
药物 / 成分:apremilast、indomethacin SR
登记的停止原因(原文):Colaborator withdrew support.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-04-02
Ghrelin and Beta Cell Function in Diabetes
编号:NCT02440061登记状态:入组前撤回企业 / 申办者:Jenny Tong, MD, MPH
药物 / 成分:Synthetic human AG、Arginine、0.9% saline solution
登记的停止原因(原文):This protocol was replaced with a different one and therefore discontinued.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-30
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
编号:NCT02204020登记状态:入组前撤回企业 / 申办者:University of Pittsburgh
药物 / 成分:5-azacytidine (5-aza) maintenance therapy after transplant
登记的停止原因(原文):Lack of interest with investigators - no subjects enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-30
Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients
编号:NCT03303677登记状态:入组前撤回企业 / 申办者:University of Florida
药物 / 成分:Saline Nasal、Budesonide Nasal、Topical Antibacterial (Product)
登记的停止原因(原文):Withdrawn by sponsor
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-29
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
编号:NCT02885545登记状态:入组前撤回企业 / 申办者:Population Health Research Institute
药物 / 成分:Watchman、Continued therapy with the prescribed oral anticoagulant
登记的停止原因(原文):Failure to recruit any participants in more than one year of recruiting.
查看官方原始记录 ↗